Patents by Inventor Bingsong Han

Bingsong Han has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds and compositions for the inhibition of NAMPT
    Patent number: 12336981
    Abstract: The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications, and antidotes.
    Type: Grant
    Filed: December 2, 2022
    Date of Patent: June 24, 2025
    Assignees: Valo Health, Inc., Genentech, Inc.
    Inventors: Kenneth W. Bair, Timm R. Baumeister, Alexandre J. Buckmelter, Karl H. Clodfelter, Peter Dragovich, Francis Gosselin, Bingsong Han, Jian Lin, Dominic J. Reynolds, Bruce Roth, Chase C. Smith, Zhongguo Wang, Po-Wai Yuen, Xiaozhang Zheng
  • 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
    Patent number: 12264137
    Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.
    Type: Grant
    Filed: March 10, 2022
    Date of Patent: April 1, 2025
    Assignee: VALO HEALTH, INC.
    Inventors: Xiaozhang Zheng, Pui Yee Ng, Bingsong Han, Jennifer R. Thomason, Mary-Margaret Zablocki, Cuixian Liu, Aleksandra Rudnitskaya, David R. Lancia, Jr., David S. Millan, Matthew W. Martin
  • PYRROLOPYRROLE COMPOSITIONS AS PYRUVATE KINASE (PKR) ACTIVATORS
    Publication number: 20240391922
    Abstract: The disclosure relates to modulating pyruvate kinase and provides novel chemical compounds useful as activators of PKR, as well as various uses of these compounds. PKR activating compounds are useful in the treatment of diseases and disorders associated with PKR and/or PKM2, such as pyruvate kinase deficiency (PKD), sickle cell disease (SCD), and thalassemia.
    Type: Application
    Filed: July 17, 2024
    Publication date: November 28, 2024
    Inventors: Anna Ericsson, Neal Green, Gary Gustafson, Bingsong Han, David R. Lancia, JR., Lorna Mitchell, David Richard, Tatiana Shelekhin, Chase C. Smith, Zhongguo Wang, Xiaozhang Zheng
  • Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators
    Patent number: 12071440
    Abstract: The disclosure relates to modulating pyruvate kinase and provides novel chemical compounds useful as activators of PKR, as well as various uses of these compounds. PKR activating compounds are useful in the treatment of diseases and disorders associated with PKR and/or PKM2, such as pyruvate kinase deficiency (PKD), sickle cell disease (SCD), and thalassemia.
    Type: Grant
    Filed: March 21, 2023
    Date of Patent: August 27, 2024
    Assignee: Novo Nordisk Health Care AG
    Inventors: Anna Ericsson, Neal Green, Gary Gustafson, Bingsong Han, David R. Lancia, Jr., Lorna Mitchell, David Richard, Tatiana Shelekhin, Chase C. Smith, Zhongguo Wang, Xiaozhang Zheng
  • Treating sickle cell disease with a pyruvate kinase R activating compound
    Patent number: 12053458
    Abstract: Compounds that activate pyruvate kinase R can be used for the treatment of sickle cell disease (SCD). Methods and compositions for the treatment of SCD are provided herein, including a therapeutic compound designated as Compound 1.
    Type: Grant
    Filed: September 19, 2019
    Date of Patent: August 6, 2024
    Assignee: Novo Nordisk Health Care AG
    Inventors: Anna Ericsson, Neal Green, Gary Gustafson, David R. Lancia, Jr., Bingsong Han, Lorna Mitchell, David Richard, Zhongguo Wang, Tatiana Shelekhin, Chase C. Smith, Xiaozhang Zheng
  • Treating sickle cell disease with a pyruvate kinase R activating compound
    Patent number: 11980611
    Abstract: Compounds that activate pyruvate kinase R can be used for the treatment of sickle cell disease (SCD). Methods and compositions for the treatment of SCD are provided herein, including a therapeutic compound designated as Compound 1.
    Type: Grant
    Filed: December 22, 2022
    Date of Patent: May 14, 2024
    Assignee: Novo Nordisk Health Care AG
    Inventors: Anna Ericsson, Neal Green, Gary Gustafson, Bingsong Han, David R. Lancia, Jr., Lorna Mitchell, David Richard, Tatiana Shelekhin, Chase C. Smith, Zhongguo Wang, Xiaozhang Zheng
  • PYRROLOPYRROLE COMPOSITIONS AS PYRUVATE KINASE (PKR) ACTIVATORS
    Publication number: 20240083901
    Abstract: The disclosure relates to modulating pyruvate kinase and provides novel chemical compounds useful as activators of PKR, as well as various uses of these compounds. PKR activating compounds are useful in the treatment of diseases and disorders associated with PKR and/or PKM2, such as pyruvate kinase deficiency (PKD), sickle cell disease (SCD), and thalassemia.
    Type: Application
    Filed: March 21, 2023
    Publication date: March 14, 2024
    Inventors: Anna ERICSSON, Neal GREEN, Gary GUSTAFSON, Bingsong HAN, David R. LANCIA, JR., Lorna MITCHELL, David RICHARD, Tatiana SHELEKHIN, Chase C. SMITH, Zhongguo WANG, Xiaozhang ZHENG
  • Alpha-cinnamide compounds and compositions as HDAC8 inhibitors
    Patent number: 11919839
    Abstract: The present invention relates to inhibitors of histone deacetylases, in particular HDAC8, that are useful for the treatment of cancer and other diseases and disorders, as well as the synthesis and applications of said inhibitors.
    Type: Grant
    Filed: April 23, 2021
    Date of Patent: March 5, 2024
    Assignee: VALO HEALTH, INC.
    Inventors: Kenneth W. Bair, Nicholas Barczak, Bingsong Han, David R. Lancia, Jr., Cuixian Liu, Matthew W. Martin, Pui Yee Ng, Aleksandra Rudnitskaya, Jennifer R. Thomason, Mary-Margaret Zablocki, Xiaozhang Zheng
  • 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
    Patent number: 11891365
    Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.
    Type: Grant
    Filed: April 23, 2021
    Date of Patent: February 6, 2024
    Assignee: VALO HEALTH, INC.
    Inventors: Xiaozhang Zheng, Pui Yee Ng, Bingsong Han, Jennifer R. Thomason, Mary-Margaret Zablocki, Cuixian Liu, Heather Davis, Aleksandra Rudnitskaya, David R. Lancia, Jr., Kenneth W. Bair, David S. Millan, Matthew W. Martin
  • [6,6] FUSED BICYCLIC HDAC8 INHIBITORS
    Publication number: 20230406830
    Abstract: The present invention is directed to compounds of Formula I: and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers or thereof, wherein R1, R2, R2?, L, X, W, Y1, Y2, Y3, and Y4 are described herein.
    Type: Application
    Filed: January 13, 2023
    Publication date: December 21, 2023
    Inventors: Xiaozhang Zheng, Pui Yee Ng, Jennifer R. Downing, Mary-Margaret Zablocki, Bingsong Han, Nicholas Barczak, Cuixian Liu, Aleksandra Rudnitskaya, David R. Lancia, JR., Kenneth W. Bair
  • TREATING SICKLE CELL DISEASE WITH A PYRUVATE KINASE R ACTIVATING COMPOUND
    Publication number: 20230381151
    Abstract: Compounds that activate pyruvate kinase R can be used for the treatment of sickle cell disease (SCD). Methods and compositions for the treatment of SCD are provided herein, including a therapeutic compound designated as Compound 1.
    Type: Application
    Filed: December 22, 2022
    Publication date: November 30, 2023
    Inventors: Anna ERICSSON, Neal GREEN, Gary GUSTAFSON, Bingsong HAN, David R. Lancia, JR., Lorna MITCHELL, David RICHARD, Tatiana SHELEKHIN, Chase C. SMITH, Zhongguo WANG, Xiaozhang ZHENG
  • NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT
    Publication number: 20230346753
    Abstract: The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes.
    Type: Application
    Filed: December 2, 2022
    Publication date: November 2, 2023
    Inventors: Kenneth W. Bair, Timm R. Baumeister, Alexandre J. Buckmelter, Karl H. Clodfelter, Peter Dragovich, Francis Gosselin, Bingsong Han, Jian Lin, Dominic J. Reynolds, Bruce Roth, Chase C. Smith, Zhongguo Wang, Po-Wai Yuen, Xiaozhang Zheng
  • NEUROACTIVE STEROIDS AND COMPOSITIONS THEREOF
    Publication number: 20230250129
    Abstract: Provided herein is a compound of the Formula (I) or a pharmaceutically acceptable salt thereof, wherein R2a, R2b, R3a, R4a, R4b, R5, R6, R7, R11a, R11b, R15a, R15b, R16, R17, R19, RX, RY, and t are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds, e.g., in the treatment of CNS-related disorders.
    Type: Application
    Filed: June 23, 2021
    Publication date: August 10, 2023
    Inventors: Bingsong Han, Maria Jesus Blanco-Pillado
  • ISOINDOLINES AS HDAC INHIBITORS
    Publication number: 20230242512
    Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs), having the formula: wherein Z, X1, X2, Y1, Y2, Y3, L, Z, and R are described herein.
    Type: Application
    Filed: November 9, 2022
    Publication date: August 3, 2023
    Inventors: Xiaozhang Zheng, Matthew W. Martin, Pui Yee Ng, Jennifer R. Thomason, Bingsong Han, Aleksandra Rudnitskaya, David R. Lancia, JR.
  • Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators
    Patent number: 11649242
    Abstract: The disclosure relates to modulating pyruvate kinase and provides novel chemical compounds useful as activators of PKR, as well as various uses of these compounds. PKR activating compounds are useful in the treatment of diseases and disorders associated with PKR and/or PKM2, such as pyruvate kinase deficiency (PKD), sickle cell disease (SCD), and thalassemia.
    Type: Grant
    Filed: April 23, 2021
    Date of Patent: May 16, 2023
    Assignee: FORMA THERAPEUTICS, INC.
    Inventors: Anna Ericsson, Neal Green, Gary Gustafson, Bingsong Han, David R. Lancia, Jr., Lorna Mitchell, David Richard, Tatiana Shelekhin, Chase C. Smith, Zhongguo Wang, Xiaozhang Zheng
  • PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT)
    Publication number: 20230110003
    Abstract: The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes.
    Type: Application
    Filed: September 9, 2022
    Publication date: April 13, 2023
    Inventors: Kenneth W. Bair, Timm R. Baumeister, Alexandre J. Buckmelter, Karl H. Clodfelter, Bingsong Han, Judith D. Kuntz, Jian Lin, Dominic J. Reynolds, Chase C. Smith, Zhongguo Wang, Xiaozhang Zheng
  • Compounds and compositions for the inhibition of NAMPT
    Patent number: 11547701
    Abstract: The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: January 10, 2023
    Assignees: Valo Health, Inc., Genentech, Inc.
    Inventors: Kenneth W. Bair, Timm R. Baumeister, Alexandre J. Buckmelter, Karl H. Clodfelter, Peter Dragovich, Francis Gosselin, Bingsong Han, Jian Lin, Dominic J. Reynolds, Bruce Roth, Chase C. Smith, Zhongguo Wang, Po-Wai Yuen, Xiaozhang Zheng
  • Isoindolines as HDAC inhibitors
    Patent number: 11535607
    Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs), having the formula: (I) wherein Z, X1, X2, Y1, Y2, Y3, L, Z, and R are described herein.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: December 27, 2022
    Assignee: Valo Health, Inc.
    Inventors: Xiaozhang Zheng, Matthew W. Martin, Pui Yee Ng, Jennifer R. Thomason, Bingsong Han, Aleksandra Rudnitskaya, David R. Lancia, Jr.
  • 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS
    Publication number: 20220363651
    Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.
    Type: Application
    Filed: April 23, 2021
    Publication date: November 17, 2022
    Inventors: Xiaozhang Zheng, Pui Yee Ng, Bingsong Han, Jennifer R. Thomason, Mary-Margaret Zablocki, Cuixian Liu, Heather Davis, Aleksandra Rudnitskaya, David R. Lancia, JR., Kenneth W. Bair, David S. Millan, Matthew W. Martin
  • Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT)
    Patent number: 11479564
    Abstract: The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes.
    Type: Grant
    Filed: September 16, 2020
    Date of Patent: October 25, 2022
    Assignee: Valo Health, Inc.
    Inventors: Kenneth W. Bair, Timm R. Baumeister, Alexandre J. Buckmelter, Karl H. Clodfelter, Bingsong Han, Judith D. Kuntz, Jian Lin, Dominic J. Reynolds, Chase C. Smith, Zhongguo Wang, Xiaozhang Zheng